دورية أكاديمية
أعرض في EDS

Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations.

التفاصيل البيبلوغرافية
العنوان: Development and Evaluation of a Physiologically Based Pharmacokinetic Model of Labetalol in Healthy and Diseased Populations.
المؤلفون: Hafsa H; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan., Zamir A; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan., Rasool MF; Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan., Imran I; Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60800, Pakistan., Saeed H; Section of Pharmaceutics, University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, Lahore 54000, Pakistan., Ahmad T; Institute for Advanced Biosciences (IAB), CNRS UMR5309, INSERM U1209, Grenoble Alpes University, 38700 La Tronche, France., Alsanea S; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Alshamrani AA; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Alruwaili AH; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Alqahtani F; Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
المصدر: Pharmaceutics [Pharmaceutics] 2022 Nov 02; Vol. 14 (11). Date of Electronic Publication: 2022 Nov 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Labetalol is a drug that exhibits both alpha and beta-adrenergic receptor-blocking properties. The American Heart Association/American Stroke Association (AHA/ASA) has recommended labetalol as an initial treatment option for the management of severe hypertension. The physiologically based pharmacokinetic (PBPK) model is an in silico approach to determining the pharmacokinetics (PK) of a drug by incorporating blood flow and tissue composition of the organs. This study was conducted to evaluate the primary reasons for the difference in PK after intravenous (IV) and oral administration in healthy and diseased (renal and hepatic) populations. A comprehensive literature search was done using two databases, PubMed and Google Scholar. Various PK parameters were screened for the development of the PBPK model utilizing a population-based PK-Sim simulator. Simulations were performed after creating building blocks firstly in healthy individuals and then in diseased patients after IV and oral administration. The disposition of labetalol after IV and oral administration occurring in patients with the hepatic and renal disease was predicted. The model was evaluated by calculating the R obs / pred ratio and average fold error (AFE), which was in the two-fold error range. Moreover, Box-whisker plots were made to compare the overall concentration of the drug in the body at various stages of disease severity. The presented model provides useful quantitative estimates of drug dosing in patients fighting against severe chronic diseases.
References: Am Fam Physician. 2007 May 15;75(10):1487-96. (PMID: 17555141)
Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):81S-86S. (PMID: 7093103)
Clin Pharmacokinet. 2010 Mar;49(3):189-206. (PMID: 20170207)
AACN Adv Crit Care. 2017 Summer;28(2):93-101. (PMID: 28592464)
Mol Pharm. 2013 Mar 4;10(3):958-66. (PMID: 23327720)
Am J Emerg Med. 2012 Jul;30(6):981-93. (PMID: 21908132)
Pharmacotherapy. 1983 Jul-Aug;3(4):193-219. (PMID: 6310529)
Clin Pharmacokinet. 2014 Apr;53(4):373-83. (PMID: 24297680)
Expert Rev Clin Pharmacol. 2011 Mar;4(2):261-74. (PMID: 22115405)
Turk Arch Otorhinolaryngol. 2019 Mar;57(1):57-58. (PMID: 31049257)
Drug Saf. 2005;28(6):529-45. (PMID: 15924505)
Expert Opin Drug Metab Toxicol. 2014 Aug;10(8):1131-43. (PMID: 24961255)
Br Med J. 1978 Oct 14;2(6144):1048-50. (PMID: 709214)
Drug Metab Dispos. 2011 Apr;39(4):571-9. (PMID: 21245286)
Drugs. 1978 Apr;15(4):251-70. (PMID: 25757)
Blood Purif. 2007;25(1):133-8. (PMID: 17170551)
J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):711-23. (PMID: 23179857)
Drugs. 1989 May;37(5):583-627. (PMID: 2663413)
Work. 2012;41 Suppl 1:4218-29. (PMID: 22317369)
Hypertension. 2003 Jun;41(6):1178-9. (PMID: 12756222)
Br J Clin Pharmacol. 1982 Jul;14(1):73-8. (PMID: 7104169)
Am J Obstet Gynecol. 1990 Feb;162(2):362-6. (PMID: 2309815)
Int J Clin Pharmacol Ther Toxicol. 1981 Jan;19(1):41-4. (PMID: 7203731)
Eur J Pharm Sci. 2014 Jun 16;57:300-21. (PMID: 24060672)
Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1397-408. (PMID: 25219632)
Drug Des Devel Ther. 2021 Mar 17;15:1195-1211. (PMID: 33762817)
Antibodies (Basel). 2022 Jun 14;11(2):. (PMID: 35735361)
J Pharm Pharmacol. 2012 Jul;64(7):997-1007. (PMID: 22686345)
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S36-S51. (PMID: 33205428)
Br J Clin Pharmacol. 1984 Sep;18(3):393-400. (PMID: 6487478)
Eur J Clin Pharmacol. 1977 Jan 3;11(2):85-90. (PMID: 14010)
CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. (PMID: 27653238)
Control Clin Trials. 1999 Oct;20(5):448-52. (PMID: 10503804)
معلومات مُعتمدة: RSP-2021/131 King Saud University
فهرسة مساهمة: Keywords: PBPK; beta blocker; drug-drug interaction; drug-food interaction; hepatic disease; labetalol; pharmacokinetics; renal failure
تواريخ الأحداث: Date Created: 20221111 Latest Revision: 20221129
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9696499
DOI: 10.3390/pharmaceutics14112362
PMID: 36365181
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics14112362